Ethmozine for ventricular premature complexes

Kathleen Gear, Frank I. Marcus, Shoei K. Huang, Paul E. Fenster, Christopher Appleton, Virginia Moeller, Gerri Renaud, Ruth Serokman

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Twenty patients with an average of more than 30 ventricular premature complexes (VPCs) per hour were treated with ethmozine. Eighteen had either not responded or had adverse reactions to at least 1 other antiarrhythmic drug. Patients were treated with 200 to 300 mg 3 times daily (8.25 to 11.7 mg/kg) and were followed for up to 6 months. Three patients were withdrawn from ethmozine therapy because of unwanted effects before evaluation of efficacy. One of these patients had sustained ventricular tachycardia (VT) after a loading dose of ethmozine. Eleven of the remaining 17 patients (65%) experienced more than a 75% reduction in ventricular ectopic activity. Six patients had a smaller or no decrease in VPC frequency. Eleven of 16 patients (68%) with paired VPCs had a more than 90% reduction in paired VPC frequency. Eleven of 13 patients (84%) with VT events of 3 beats or more had more than a 90% reduction in VT events. Of the 11 patients in whom a more than 75% reduction in VPC frequency occurred, 1 patient died suddenly after 133 days of effective drug therapy. Three patients discontinued ethmozine therapy for reasons not related to the drug. Of the 6 patients in whom there was less than a 75% reduction in VPC frequency, 2 patients discontinued treatment, 1 patient because of hyperanxiety and 1 because of drug-related left anterior hemiblock. Ethmozine lengthened PR and QRS intervals but not the JT interval. Thus, ethmozine is effective and clinically useful for suppression of frequent VPCs in 50% (10 of 20 patients) of a selected population.

Original languageEnglish (US)
Pages (from-to)947-949
Number of pages3
JournalThe American Journal of Cardiology
Volume57
Issue number11
DOIs
StatePublished - Apr 15 1986
Externally publishedYes

Fingerprint

Moricizine
Ventricular Premature Complexes
Ventricular Tachycardia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Gear, K., Marcus, F. I., Huang, S. K., Fenster, P. E., Appleton, C., Moeller, V., ... Serokman, R. (1986). Ethmozine for ventricular premature complexes. The American Journal of Cardiology, 57(11), 947-949. https://doi.org/10.1016/0002-9149(86)90736-8

Ethmozine for ventricular premature complexes. / Gear, Kathleen; Marcus, Frank I.; Huang, Shoei K.; Fenster, Paul E.; Appleton, Christopher; Moeller, Virginia; Renaud, Gerri; Serokman, Ruth.

In: The American Journal of Cardiology, Vol. 57, No. 11, 15.04.1986, p. 947-949.

Research output: Contribution to journalArticle

Gear, K, Marcus, FI, Huang, SK, Fenster, PE, Appleton, C, Moeller, V, Renaud, G & Serokman, R 1986, 'Ethmozine for ventricular premature complexes', The American Journal of Cardiology, vol. 57, no. 11, pp. 947-949. https://doi.org/10.1016/0002-9149(86)90736-8
Gear K, Marcus FI, Huang SK, Fenster PE, Appleton C, Moeller V et al. Ethmozine for ventricular premature complexes. The American Journal of Cardiology. 1986 Apr 15;57(11):947-949. https://doi.org/10.1016/0002-9149(86)90736-8
Gear, Kathleen ; Marcus, Frank I. ; Huang, Shoei K. ; Fenster, Paul E. ; Appleton, Christopher ; Moeller, Virginia ; Renaud, Gerri ; Serokman, Ruth. / Ethmozine for ventricular premature complexes. In: The American Journal of Cardiology. 1986 ; Vol. 57, No. 11. pp. 947-949.
@article{1d21aeb7104147cd95d36e124b91e457,
title = "Ethmozine for ventricular premature complexes",
abstract = "Twenty patients with an average of more than 30 ventricular premature complexes (VPCs) per hour were treated with ethmozine. Eighteen had either not responded or had adverse reactions to at least 1 other antiarrhythmic drug. Patients were treated with 200 to 300 mg 3 times daily (8.25 to 11.7 mg/kg) and were followed for up to 6 months. Three patients were withdrawn from ethmozine therapy because of unwanted effects before evaluation of efficacy. One of these patients had sustained ventricular tachycardia (VT) after a loading dose of ethmozine. Eleven of the remaining 17 patients (65{\%}) experienced more than a 75{\%} reduction in ventricular ectopic activity. Six patients had a smaller or no decrease in VPC frequency. Eleven of 16 patients (68{\%}) with paired VPCs had a more than 90{\%} reduction in paired VPC frequency. Eleven of 13 patients (84{\%}) with VT events of 3 beats or more had more than a 90{\%} reduction in VT events. Of the 11 patients in whom a more than 75{\%} reduction in VPC frequency occurred, 1 patient died suddenly after 133 days of effective drug therapy. Three patients discontinued ethmozine therapy for reasons not related to the drug. Of the 6 patients in whom there was less than a 75{\%} reduction in VPC frequency, 2 patients discontinued treatment, 1 patient because of hyperanxiety and 1 because of drug-related left anterior hemiblock. Ethmozine lengthened PR and QRS intervals but not the JT interval. Thus, ethmozine is effective and clinically useful for suppression of frequent VPCs in 50{\%} (10 of 20 patients) of a selected population.",
author = "Kathleen Gear and Marcus, {Frank I.} and Huang, {Shoei K.} and Fenster, {Paul E.} and Christopher Appleton and Virginia Moeller and Gerri Renaud and Ruth Serokman",
year = "1986",
month = "4",
day = "15",
doi = "10.1016/0002-9149(86)90736-8",
language = "English (US)",
volume = "57",
pages = "947--949",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Ethmozine for ventricular premature complexes

AU - Gear, Kathleen

AU - Marcus, Frank I.

AU - Huang, Shoei K.

AU - Fenster, Paul E.

AU - Appleton, Christopher

AU - Moeller, Virginia

AU - Renaud, Gerri

AU - Serokman, Ruth

PY - 1986/4/15

Y1 - 1986/4/15

N2 - Twenty patients with an average of more than 30 ventricular premature complexes (VPCs) per hour were treated with ethmozine. Eighteen had either not responded or had adverse reactions to at least 1 other antiarrhythmic drug. Patients were treated with 200 to 300 mg 3 times daily (8.25 to 11.7 mg/kg) and were followed for up to 6 months. Three patients were withdrawn from ethmozine therapy because of unwanted effects before evaluation of efficacy. One of these patients had sustained ventricular tachycardia (VT) after a loading dose of ethmozine. Eleven of the remaining 17 patients (65%) experienced more than a 75% reduction in ventricular ectopic activity. Six patients had a smaller or no decrease in VPC frequency. Eleven of 16 patients (68%) with paired VPCs had a more than 90% reduction in paired VPC frequency. Eleven of 13 patients (84%) with VT events of 3 beats or more had more than a 90% reduction in VT events. Of the 11 patients in whom a more than 75% reduction in VPC frequency occurred, 1 patient died suddenly after 133 days of effective drug therapy. Three patients discontinued ethmozine therapy for reasons not related to the drug. Of the 6 patients in whom there was less than a 75% reduction in VPC frequency, 2 patients discontinued treatment, 1 patient because of hyperanxiety and 1 because of drug-related left anterior hemiblock. Ethmozine lengthened PR and QRS intervals but not the JT interval. Thus, ethmozine is effective and clinically useful for suppression of frequent VPCs in 50% (10 of 20 patients) of a selected population.

AB - Twenty patients with an average of more than 30 ventricular premature complexes (VPCs) per hour were treated with ethmozine. Eighteen had either not responded or had adverse reactions to at least 1 other antiarrhythmic drug. Patients were treated with 200 to 300 mg 3 times daily (8.25 to 11.7 mg/kg) and were followed for up to 6 months. Three patients were withdrawn from ethmozine therapy because of unwanted effects before evaluation of efficacy. One of these patients had sustained ventricular tachycardia (VT) after a loading dose of ethmozine. Eleven of the remaining 17 patients (65%) experienced more than a 75% reduction in ventricular ectopic activity. Six patients had a smaller or no decrease in VPC frequency. Eleven of 16 patients (68%) with paired VPCs had a more than 90% reduction in paired VPC frequency. Eleven of 13 patients (84%) with VT events of 3 beats or more had more than a 90% reduction in VT events. Of the 11 patients in whom a more than 75% reduction in VPC frequency occurred, 1 patient died suddenly after 133 days of effective drug therapy. Three patients discontinued ethmozine therapy for reasons not related to the drug. Of the 6 patients in whom there was less than a 75% reduction in VPC frequency, 2 patients discontinued treatment, 1 patient because of hyperanxiety and 1 because of drug-related left anterior hemiblock. Ethmozine lengthened PR and QRS intervals but not the JT interval. Thus, ethmozine is effective and clinically useful for suppression of frequent VPCs in 50% (10 of 20 patients) of a selected population.

UR - http://www.scopus.com/inward/record.url?scp=0022454733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022454733&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(86)90736-8

DO - 10.1016/0002-9149(86)90736-8

M3 - Article

C2 - 2421571

AN - SCOPUS:0022454733

VL - 57

SP - 947

EP - 949

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 11

ER -